FOR THYROID BLOCKING IN A RADIATION EMERGENCY.http://www.anbex.com/index.php
Following the meltdown at Three Mile Island nuclear plant in 1979, ANBEX developed iOSAT™ for protection from an accidental or terrorist related release of radioactive iodine from a nuclear power plant or nuclear weapon.
iOSAT™ received its approval from the US Food and Drug Administration in 1982, and is the only full-strength tablet for radiation blocking which may legally be sold in the US.
Only iOSAT™ has passed all FDA tests for purity, quality, safety and efficacy.
iOSAT™: $10 per package for quantities up to 10.
For each 10 packages purchased the Customer will get one FREE.
There are 14 130mg tablets in each package.
Bulk sale of iOSAT™: for government, military and health department stockpiling.
WHAT IS THE DAILY DOSAGE REQUIRED?
New FDA guidelines call for the daily administration of one iOSAT tablet (130 mg. of potassium iodide (KI)) for adults and children over 18 years old who weigh more that 150 pounds.
Children from age 3 to 18 years old who weigh less than 150 pounds should take ½ tablet.
Children from age one month to 3 years should take ¼ tablet.
And infants less than one month old should take ¼ tablet.
If necessary, children too young to take solid food or unable to swallow a tablet can take iOSAT™ dissolved in a liquid (such as chocolate milk) or in a soft food such as applesauce.
HOW LONG DOES THE PROTECTION LAST?
Each iOSAT™ Tablet provides 24 hours of protection.
DOES KI HELP PREVENT OTHER CANCERS THAT MIGHT OCCUR OTHER PLACES IN THE BODY?
iOSAT™ only protects against radioactive iodine which can injure the thyroid and cause thyroid cancer, thyroid nodules, and other thyroid problems.
The product is essentially ineffective against other radioactive products.
However, since radioactive iodine would probably be the cause of 90% to 95% of all "off-site" injuries in a power-plant accident, the protection provided by iOSAT™ is extremely valuable.
(At Chernobyl, for example, thyroid cancer, which is now epidemic in some areas as a result of the accident, was the only health effect seen in areas more than a few miles from the plant.)
WHAT IS THE US GOVERNMENT'S POSITION ON PROVIDING KI TO WORKERS AND THE PUBLIC IN THE EVENT OF ANOTHER NUCLEAR EMERGENCY?
The US Nuclear Regulatory Commission (NRC) does not dispute the safety or effectiveness of KI. In fact, they require nuclear power-plants to stockpile it to protect plant workers, and FEMA
(Federal Emergency Management Agency) plans call for KI to protect those individuals who would be unable to be evacuated in a nuclear accident - especially those under the care of the government (such as prisoners or patients in government hospitals).
But the NRC is resisting the calls for a national stockpile of KI, claiming it is "unnecessary."
As a result, the US remains the only major nuclear power that does not have a supply to protect its citizens.
Recently, to counter the widespread criticism of this policy, the government announced it had established a "national stockpile" of KI.
This news was welcomed by many in the scientific community.
However, at a recent meeting, the NRC admitted that its operational "national stockpile" consisted of only 2500 tablets, not even enough for 200 people.
As a reaction to criticism by US medical groups and the World Health Organization, the NRC has announced it would make KI available (free of charge) to state or local governments desiring it.
Again, this news was greeted with enthusiasm.
However, following this announcement, the NRC "clarified" its position, and now says it will provide KI only to those people living in communities within the 10 mile "EPZ" (Emergency Planning Zone) surrounding nuclear plants.
Given that most casualties in a nuclear accident would take place more than 50 miles from the plant (following Chernobyl, thousands of cases of childhood thyroid cancer developed hundreds of miles away), the current NRC position is probably of questionable value.
